1. NYX‐458 Improves Cognitive Performance in a Primate Parkinson's Disease Model. Issue 4 (22nd January 2020) Authors: Barth, A.L; Schneider, J.S.; Johnston, T.H.; Hill, M.P.; Brotchie, J.M.; Moskal, J.R.; Cearley, Cassia N. Journal: Movement disorders Issue: Volume 35:Issue 4(2020) Page Start: 640 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P 15 Long-term subthalamic deep brain stimulation modulates pathological beta oscillations in the AAV-A53T-Synuclein Parkinson's disease rat model. (May 2022) Authors: Chen, J.Z.; Hofman, K.; Koprich, J.B.; Brotchie, J.M.; Volkmann, J.; Ip, C.W. Journal: Clinical neurophysiology Issue: Volume 137(2022) Page Start: e23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P 5 MCC950 treatment reduces neuroinflammation, rescues neuronal cell death and ameliorates motor deficits in the AAV1/2-A53T-αSyn mouse model of Parkinson's disease. (May 2022) Authors: Grotemeyer, A.; Fischer, J.; Koprich, J.B.; Brotchie, J.M.; Volkmann, J.; Ip, C.W. Journal: Clinical neurophysiology Issue: Volume 137(2022) Page Start: e17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P 77 Pathological local field potential during the awake state in the progressive AAV-A53T-aSyn Parkinson's disease rat model. (May 2022) Authors: Hofman, K.; Chen, J.Z.; Petschner, T.; Koprich, J.B.; Brotchie, J.M.; Volkmann, J.; Ip, C.W. Journal: Clinical neurophysiology Issue: Volume 137(2022) Page Start: e59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Special Issue on new therapeutic approaches to Parkinson disease. (1st May 2022) Authors: Fox, S.H.; Brotchie, J.M. Journal: Neuropharmacology Issue: Volume 208(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques. (September 2020) Authors: Depoortere, R.; Johnston, T.H.; Fox, S.H.; Brotchie, J.M.; Newman-Tancredi, A. Journal: Parkinsonism & related disorders Issue: Volume 78(2020) Page Start: 151 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗